Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma by Ajay K. Gopal, Joseph G. Rajendran, Stephen H. Petersdorf, David G. Maloney, Janet F. Eary, Brent L. Wood, Theodore A. Gooley, Sharon A. Bush, Lawrence D. Durack, Paul J. Martin, Dana C. Matthews, Frederick R. Appelbaum, Irwin D. Bernstein, and Oliver W. Press Blood Volume 99(9):3158-3162 May 1, 2002 ©2002 by American Society of Hematology Treatment schema for high-dose chemo-radioimmunotherapy.PBSC indicates peripheral blood stem cells. *The day of treatment is listed only to give a loose time frame. Ajay K. Gopal et al. Blood 2002;99:3158-3162 ©2002 by American Society of Hematology Overall and progression-free survival from the time of transplantation of 16 patients with relapsed mantle cell lymphoma treated with 131I-Tositumomab, etoposide, cyclophosphamide, and autologous stem cell transplantation. Ajay K. Gopal et al. Blood 2002;99:3158-3162 ©2002 by American Society of Hematology